Combined treatment with ligands for both RXR and PPARγ leads to additive inhibition of MMP-1 and MMP-13 production, suggesting that these compounds could be used together, in lower doses than single-drug treatment, to reduce or block joint destruction in arthritis, thus minimizing the risk of adverse side effects. The gene discussed is PPARG; the disease is arthritic joint disease.